

Bioorganic & Medicinal Chemistry 8 (2000) 37-42

BIOORGANIC & MEDICINAL CHEMISTRY

Reactions of a Series of 1-Aminobenzimidazoles and 1-Amino-3methylbenzimidazolium Chlorides with 2,4-Pentanedione

Toyo Kaiya, Shinsuke Aoyama and Kohfuku Kohda*

Faculty of Pharmaceutical Sciences, Nagoya City University, Tanabedori, Mizuho-ku, Nagoya 467-8603, Japan

Received 14 June 1999; accepted 19 August 1999

Abstract—Reactions of a series of 1-aminobenzimidazoles and 1-amino-3-methylbenzimidazolium chlorides with 2,4-pentanedione were carried out and pyridazino[1,6-*a*]benzimidazoles and 2-pyrazolylanilines were generated. The product ratios of these compounds remarkably depended on the reaction conditions and on the electronic character of the substituent at the benzene moiety. The possible mechanisms involved in these reactions are discussed. © 2000 Elsevier Science Ltd. All rights reserved.

Introduction

In order to elucidate the chemical carcinogenesis of arylaminating carcinogens, we have examined electrophilic amination of nucleic acid components.¹ To date, we have generated all isomers of ring-nitrogen mono-aminated bases and nucleosides of nucleic acid components.²⁻⁶ As a model for the imidazole moiety of purines, we also examined electrophilic amination of a series of benzimidazole derivatives.⁷ In a report on the utilization of N-aminated derivatives, we previously described the formation of pyridazinopurine derivatives, new tricyclic compounds, by the reaction of 7- or 9aminoadenine derivatives with 2,4-pentanedione⁸ (Scheme 1). In the case of 7-aminoadenines, 5-pyrazolylpyrimidines were also obtained as by-products. This study was carried out to elucidate the reaction mechanisms responsible for formation of these products using a series of 1-aminobenzimidazole and 1-amino-3methylbenzimidazolium chloride derivatives.

Results and Discussion

Reactions of 1-aminobenzimidazoles (1) with 2,4-pentanedione

Each 1-aminobenzimidazole (1a–c) was dissolved in a large excess of 2,4-pentanedione and refluxed for 4h.

Products were then separated and identified (Scheme 2 and Table 1). From compounds 1a,b, pyridazino[1,6a]benzimidazoles (3a,b) were obtained in yields of 78 and 97%, respectively, as already reported.9 Compound 1c has an electron-withdrawing substituent at the benzene moiety, and when it was allowed to react with 2,4-pentanedione, no product corresponding to compound 3 was produced, although 2-pyrazolylaniline (4c) was obtained in a low yield of 17%. In this case, the starting material, 1c, remained, indicating that the reaction had proceeded slower than with 1a,b. The structures of compounds 3a,b and 4c were determined from spectroscopic data (details of 4c will be described later). Assignments of ¹H and ¹³C NMR signals of these compounds were carried out by means of HMBC correlations. In the reaction of 1 with 2,4-pentanedione in the presence of a catalytic amount of ZnCl₂, compound 1a afforded a quantitative yield of 3a, however, compound 1b gave 3b and 5b, each in a 27% yield.

Compound **5b** will be formed from compound **4b** by further reaction of its amino group with 2,4-pentanedione to form a Schiff base. In the case of **1c**, the starting material was completely consumed and the reaction gave several products, however, only one product, **5c**, was identified with a very low yield (details of the structure will be described later). These results suggested that the types and ratios of the products remarkably depended on the substituent at the benzene moiety and on the presence or absence of a Lewis acid. With respect to the reaction of **1c**, we used a 1:1 mixture of 1-amino-5-nitrobenzimidazole and 1-amino-6-nitrobenzimidazole because of the difficulty in separating these two isomers. It was interesting that compound **1c** gave only

Keywords: N-aminobenzimidazole; 2,4-pentanedione; pyridazinobenzimidazole; chemical carcinogenesis. *Corresponding author. Tel.: +81-52-836-3796; fax: +81-52-834-9309; e-mail: kohda@phar.nagoya-cu.ac.jp



Scheme 1. Reactions of N-aminoadenines with 2,4-pentanedione.



Scheme 2. Reactions of 1-aminobenzimidazole derivatives with 2,4-pentanedione.

the 4-nitro derivative of 4 ($R^1=NO_2$, $R^2=H$) when 1c was allowed to react with 2,4-pentanedione in the absence of a Lewis acid, whereas in the presence of ZnCl₂, the reaction gave only the 5-nitro derivative of 5 ($R^1=H$, $R^2=NO_2$). These results indicated that the reactivity of 1-amino-5-nitrobenzimidazole and 1-amino-6-nitrobenzimidazole toward 2,4-pentanedione was altered by the presence of ZnCl₂. The effect of another Lewis acid, AlCl₃, on the reaction of 1b was also examined, and results showed that the yield of 5b was lower than with ZnCl₂ (Table 1). With respect to the tautomeric structures of 5b,c, the ¹H NMR spectra showed that they are in the enol form as is 2b, as shown in Scheme 2.

HPLC study of reaction pathways

The reaction pathway of **1b** with 2,4-pentanedione was examined using HPLC. Compound **1b** was allowed to react with 2,4-pentanedione under the same reaction conditions described above. Identification and quantification of products **1b**, **2b**, **3b** and **5b** were carried out at the appropriate times. In the absence of a Lewis acid, the reaction mixture after 30 min contained starting material **1b** and products **2b** and **3b**. After 2 h, the starting material had been totally consumed and product **3b** was the major product along with a smaller amount of **2b**. In the presence of ZnCl₂, the reaction mixture contained no starting material after 30 min, and product **2b** was the major product with smaller amounts of products **3b** and **5b**. After 2 h, a decreased amount of product **2b** and an increased amount of products **3b** and **5b** were noted. No product corresponding to compound **4** was observed, suggesting that the amino group of product **4**, once formed, was converted to Schiff base **5** very quickly by further reaction with 1,2-pentanedione.

These results strongly suggested that the Schiff base product **2b** is the first to yield products **3b** and **5b**. For further confirmation of the reaction pathway, compound **2b** was obtained as an oil from the reaction mixture in which **1b** and 2,4-pentanedione were refluxed for 30 min (Table 1). Compound **2b** was then allowed to react with 2,4-pentanedione in the presence or absence of ZnCl₂, and product analyses were carried out using HPLC. In the absence of ZnCl₂, a decreased amount of **2b** and an increased amount of **3b** were obtained after 30 min, but after 2 h, only compound **3b** was observed. In the presence of ZnCl₂, products **3b** and **5b** appeared after 30 min with a decreased amount of **2b**, and after

Table 1. Reactions of 1-aminoobenzimidazoles (1) with 2,4-pentane-dione and yields of products a

Starting material	Lewis acid	Reaction time (h)	Yields of products (%) ^b				Comments
			2	3	4	5	•
1a	None	4		78			
1b	None	4		97			
1c ^c	None	4			17 ^d		f
1a	ZnCl ₂	4		100			
1b	$ZnCl_{2}$	4		27		27	
1c ^c	$ZnCl_2$	4				6 ^e	g
1b	None	0.5	23	5			f
1b	$AlCl_3$	4		25		5	
2b	None	4		88			
2b	$ZnCl_2$	4		18		21	

^aA solution of **1** or **2** (0.5 mmol) in 1,2-pentanedione (10 mL) was refluxed for 0.5 or 4 h in the presence or absence of a Lewis acid (10 mg). ^bIsolation yield.

^cA 1:1 mixture (R^1 =NO₂, R^2 =H and R^1 =H, R^2 =NO₂) was used (Scheme 2).

 $^{d}R^{1} = NO_{2}, R^{2} = H.$

 ${}^{e}R^{1}=H, R^{2}=NO_{2}.$

fStarting material remained.

^gUnidentified products were included.

2 h, products **3b** and **5b** predominated with only a trace amount of **2b** remaining.

Reactions of 1-amino-3-methylbenzimidazolium chlorides (6) with 2,4-pentanedione

Similar reactions were carried out with 2,4-pentanedione and compounds **6**, the quaternary salts of **1** (Table 2). Since these reactions did not proceed well without ZnCl₂, this Lewis acid was included in the reactions. Four derivatives of 1-amino-3-methylbenzimidazolium chlorides (**6a–d**) were employed. Although the yields of products were low, 2,4,5-trimethylpyridazino[1,6-*a*]benzimidazolium chlorides (**7a–c**) and 2-(4-acetyl-3-methylpyrazol-1-yl)-*N*-methylanilines (**8a–c**) were obtained from **6a–c**. In contrast, compound **6d**, which has an electron-withdrawing substituent at the benzene moiety, produced **8d** and no **7d**. These results were similar to those obtained with 1c, as shown in Table 1. Structures of products 8 were determined mainly by means of ¹H and ¹³C NMR spectroscopies and HMBC correlation analyses. Unequivocal structural determination of 8 was carried out with products 8c,d, and the structures of 8a,b were determined by comparing their spectroscopic data with those of 8c,d. Unequivocal structural determination of product 7 was not successful because 7 is a quaternary ammonium salt and its purification and crystallization could not be achieved. However, there is strong evidence for the structure of 7 in that the UV spectrum of 7c in H_2O $(\lambda_{max} 236 \text{ and } 309 \text{ nm})$ was quite similar to that of **3b** in acidic media (the protonation site may be at N5 and the λ_{max} were 235 and 308 nm). Moreover, spots of both 3 and 7 on TLC fluoresced a light blue and purplish blue color, respectively, when exposed to UV light.

Proposed reaction mechanisms

In the reaction of 1-aminobenzimidazoles (1) with 2.4pentanedione, the initial step of the reaction is the formation of Schiff base product 2 (Scheme 3). Products 3 and 4 will be formed by cyclization at C2 and C3' and subsequent aromatization, and by cyclization at C2 and C2' and subsequent C2-N3 bond cleavage of the imidazole ring, respectively. Product 5 is formed by the further reaction of 4 with 2,4-pentanedione. When the electron density of the imidazole moiety is decreased by the introduction of an electron-withdrawing substituent at the benzene moiety (compound 1c) or by the presence of a Lewis acid, the reaction pathway forming compound 4 or 5 is favored. Similarly, in the reaction of 1-amino-3-methylbenzimidazolium chlorides 6 with 2,4-pentanedione, a Schiff base is formed initially and its cyclization at C2 and C2' gives 8 (Scheme 4). For formation of 7, the carbanion at C2 may attack the carbonyl carbon of the side chain to form 7, although we have no evidence supporting the participation of the carbanion in this reaction as yet. Formation of similar types of cationic tricyclic system using other procedures¹⁰ and description of similar types of reaction mechanisms¹¹ have been reported by others.



Table 2. Reactions of 1-amino-3-methylbenzimidazolium chlorides (6) with 2,4-pentanedione and yields of products

^aA product was formed but not isolated.



Scheme 3. Proposed reaction mechanisms.



Scheme 4. Proposed reaction mechanisms.

Experimental

¹H and ¹³C NMR spectra were recorded on JEOL EX 270, GSX 400 and ALPHA 500 spectrometers, and chemical shifts are expressed in parts per million downfield from internal tetramethylsilane. Mass spectra were obtained with JEOL AX 505HA and SX 102A spectrometers. UV spectra were recorded on a Shimadzu UV-2100 spectrophotometer and pKa values were estimated from pH-dependent UV spectral changes. HPLC analyses were carried out using a Shimadzu LC-10AD apparatus equipped with a photodiode array UV detector SPD-M6A. A Merck LiChrospher 100RP-18(e) column (4×250 mm) was used and eluted with a solvent system of 1/15 M phosphate buffer (pH 6.8)-MeOH (a linear gradient of 20% MeOH at 0 min to 70% MeOH at 40 min at a flow rate of 0.8 mL/min). Melting points (Mp) were measured with a Yanagimoto micro-melting point apparatus and are uncorrected. Preparative thinlayer chromatography (PLC) was carried out with Merck silica gel 60 PF254 plates. 1-Aminobenzimidazole¹² and 1-amino-5,6-dimethylbenzimidazole¹³ were prepared as previously reported. 1-Amino-3-methylbenzimidazolium chloride derivatives¹⁴ were also prepared as previously described.

Preparation of a 1:1 mixture of 1-amino-5-nitrobenzimidazole and 1-amino-6-nitrobenzimidazole (1c). 5-Nitrobenzimidazole (82 mg, 0.5 mmol) was dissolved in 5 mL of water containing KOH (84 mg, 1.5 mmol). Then, 5 mL of water containing hydroxylamine-O-sulfonic acid (170 mg, 1.5 mmol) and NaHCO₃ (126 mg, 1.5 mmol) were added to this solution, and the mixture was heated at 60 °C for 2h. The reaction mixture was then neutralized with acetic acid and the solvent was removed by evaporation to dryness. Products were extracted from the residue with MeOH and separated by repeated PLC (silica gel, CHCl₃:MeOH = 85:15). Colorless crystals of a 1:1 mixture of 1-amino-5-nitobenzimidazole (5-NO₂) and 1-amino-6-nitobenzimidazole (6-NO₂) were obtained in a 44 mg (49%) yield. The extent of recovery of the starting material was 28 mg (34%). ¹H NMR (CDCl₃) (pairs of signals having the same heights were observed) δ 4.99 and 5.02 (each s, each 2H, NH₂ of 5-NO₂ and 6-NO₂), 7.57 and 7.84 (each d, each 1H, each J=9.0 Hz, 7-H of 5-NO₂, 4-H of 6-NO₂), 8.15 and 8.22 (each s, each 1H, 2-H of 5-NO₂ and 6-NO₂), 8.22 and 8.29 (each dd, each 1H, each J = 2.2, 9.0 Hz, 6-H of 5-NO₂, 5-H of 6-NO₂), 8.46 and 8.70 (each d, each 1H, each J = 2.2 Hz, 4-H of 5-NO₂, 7-H of 6-NO₂); MS m/z 178 (M⁺). HRMS m/z M⁺ calcd for C₇H₆N₄O₂: 178.0491; found: 178.0491.

General procedure for the reactions of 1-aminobenzimidazoles (1) with 2,4-pentanedione

Each 1-aminobenzimidazole derivative (1a–c, 0.5 mmol) was dissolved in 2,4-pentanedione (10 mL) and the solution was refluxed for 4 h in the presence or absence of $ZnCl_2$ (10 mg). After the reaction, 2,4-pentanedione was removed by evaporation and the residues were subjected to PLC (silica gel, CHCl₃:MeOH=95:5).

2,4,7,8-Tetramethylpyridazino[1,6-*a*]benzimidazole (3a).⁹ ¹H NMR (CDCl₃) δ 2.46 and 2.48 (each s, each 3H, 7and 8-CH₃), 2.59 (s, 3H, 2-CH₃), 2.69 (s, 3H, 4-CH₃), 6.89 (s, 1H, 3-H), 7.70 (s, 1H, 6-H), 7.87 (s, 1H, 9-H); ¹³C NMR (CDCl₃) δ 16.9 (q, 4-CH₃), 20.6 and 20.8 (each q, 7- and 8-CH₃), 21.5 (q, 2-CH₃), 111.4 (d, 9-C), 119.8 (d, 6-C), 121.3 (d, 3-C), 129.3 (s, 5a-C), 132.1 (s, 7-C), 135.0 (s, 8-C), 136.6 (s, 4a-C), 141.5 and 142.6 (each s, 4- and 9a-C), 149.4 (s, 2-C); MS *m*/*z* 225 (M⁺).

2,4-Dimethylpyridazino[1,6-*a*]benzimidazole (3b).⁹ Recrystallization from CHCl₃-hexane gave colorless plates. Mp 139–141 °C; ¹H NMR (CDCl₃) δ 2.60 (s, 3H, 2-CH₃), 2.70 (s, 3H, 4-CH₃), 6.92 (s, 1H, 3-H), 7.42 (t, 1H, J=7.3 Hz, 7-H), 7.52 (t, 1H, J=7.3 Hz, 8-H), 7.96 (d, 1H, J=7.3 Hz, 6-H), 8.11 (d, 1H, J=7.3 Hz, 9-H); ¹³C NMR (CDCl₃) δ 16.9 (q, 4-CH₃), 21.6 (q, 2-CH₃), 111.8 (d, 9-C), 120.2 (d, 6-C), 122.2 (d, 3-C), 122.4 (d, 7-C), 125.5 (d, 8-C), 130.8 (s, 5a-C), 136.8 (s, 4a-C), 142.7 (s, 9a-C), 143.3 (s, 4-C), 150.0 (s, 2-C); UV λ_{max} nm, (pH 1) 235, 308, (H₂O and pH 12) 243, 316; pK_a 4.3; MS m/z 197 (M⁺). Anal. calcd for C₁₂H₁₁N₃: C, 73.03; H, 5.62; N, 21.30. Found: C, 73.33; H, 5.70; N, 21.16.

2-(4-Acetyl-3-methylpyrazol-1-yl)-4-nitroaniline (4c). Recrystallization from MeOH gave yellow needles. Mp 218–220 °C; ¹H NMR (Me₂SO- d_6) δ 2.44 (s, 3H, 3'-CH₃), 2.45 (s, 3H, COCH₃), 6.96 (d, 1H, J=9.0 Hz, 6-H), 7.03 (br s, 2H, NH₂), 8.06 (dd, 1H, J=2.4, 9.0 Hz, 5-H), 8.21 (d, 1H, J=2.4 Hz, 3-H), 8.96 (s, 1H, 5'-H); ¹³C NMR (Me₂SO- d_6) δ 13.7 (q, CH₃), 28.5 (q, COCH₃), 115.3 (d, 6-C), 121.0 (s, 4'-C), 121.2 (d, 3-C), 122.2 (s, 2-C), 125.1 (d, 5-C), 135.5 (s, 4-C), 136.9 (d, 5'-C), 148.9 (s, 1-C), 150.4 (s, 3'-C), 192.5 (s, COCH₃); MS m/z 260 (M⁺), 245 (M⁺-CH₃). Anal. calcd for C₁₂H₁₂N₄O₃: C, 55.38; H, 4.65; N, 21.53. Found: C, 55.02; H, 4.68; N, 21.20.

2-(4-Acetyl-3-methylpyrazol-1-yl)-*N*-(**3-hydroxy-1-methyl-2-butenylidene)aniline** (**5b**). Recrystallization from MeOH gave brown plates. Mp 161–163 °C; ¹H NMR (CDCl₃) δ 1.62 (s, 3H, 1'-CH₃), 2.09 (s, 3H, 3'-CH₃), 2.38 (s, 3H, COCH₃), 2.55 (s, 3H, 3"-CH₃), 5.20 (s, 1H, 2'-H), 7.29 (m, 1H, 5-H), 7.40 (m, 2H, 3- and 6-H), 7.71 (m, 1H, 4-H), 8.14 (s, 1H, 5"-H), 12.30 (br s, OH); ¹³C NMR (CDCl₃) δ 14.0 (q, 3"-CH₃), 19.2 (q, 1'-CH₃), 28.5 (q, COCH₃), 29.2 (q, 4'-C), 98.3 (d, 2'-C), 122.3 (s, 4"-C),

125.7 (d, 4-C), 127.9 and 128.2 (each d, 3- and 6-C), 128.5 (d, 5-C), 131.2 (s, 2-C), 135.1 (d, 5"-C), 135.7 (s, 1-C), 151.8 (s, 3"-C), 160.6 (s, 1'-C), 192.7 (s, COCH₃), 197.0 (s, 3'-C); MS m/z 297 (M⁺), 282 (M⁺-CH₃), 254 (M⁺-COCH₃), 240 (M⁺-CH=C(OH)-CH₃). Anal. calcd for C₁₇H₁₉N₃O₂: C, 68.67; H, 6.44; N, 14.13. Found: C, 68.54; H, 6.42; N, 14.15.

2-(4-Acetyl-3-methylpyrazol-1-yl)-*N*-(**3-hydroxy-1-methyl-2-butenylidene**)-**5-nitroaniline** (**5c**). Recrystallization from MeOH gave a yellow flocculi. Mp 200–202 °C; ¹H NMR (Me₂SO-*d*₆) δ 2.01 (s, 3H, 3'-CH₃), 2.08 (s, 3H, 1'-CH₃), 2.43 (s, 3H, COCH₃), 2.45 (s, 3H, 3''-CH₃), 5.43 (s, 1H, 2'-H), 7.74 (d, 1H, *J*=9.0 Hz, 3-H), 8.26 (dd, 1H, *J*=2.3, 9.0 Hz, 4-H), 8.43 (d, 1H, *J*=2.3 Hz, 6-H), 8.96 (s, 1H, 5''-H), 12.49 (br s, OH); MS *m*/*z* 342 (M⁺), 327 (M⁺-CH₃), 299 (M⁺-COCH₃), 285 (M⁺-CH=C(OH)-CH₃). HRMS *m*/*z* M⁺ calcd for C₁₇H₁₈N₄O₄: 342.1328; found: 342.1328. Anal. calcd for C₁₇H₁₈N₄O₄: 2/3H₂O: C, 57.62; H, 5.50; N, 15.81. Found: C, 57.32; H, 5.17; N, 15.78.

1-(3-Hydroxy-1-methyl-2-butenylideneamino)benzimidazole (**2b**). ¹H NMR (CDCl₃) δ 1.71 (s, 3H, 1'-CH₃), 2.19 (s, 3H, 3'-CH₃), 5.38 (s, 1H, 2'-CH), 7.34 (m, 3H, 5-, 6-H and 4- or 7-H), 7.81 (dd, 1H, J=1.8, 6.7 Hz, 7- or 4-H), 7.94 (s, 1H, 2-H), 12.28 (br s, 1H, OH); ¹³C NMR (CDCl₃) δ 17.1 (q, 1'-CH₃), 29.5 (q, 4'-C), 99.2 (d, 2'-C), 108.9 and 121.0 (each d, 4- and 7-C), 123.2 and 124.4 (each d, 5 and 6-C), 133.8 and 141.3 (each s, 3a- and 7a-C), 142.8 (d, 2-C), 161.1 (s, 1'-C), 198.4 (s, 3'-C); MS *m*/*z* 215 (M⁺), 200 (M⁺-CH₃), 198 (M⁺-OH).

General procedure for the reactions of 1-amino-3-methylbenzimidazolium chlorides (6) with 2,4-pentanedione

Each 1-amino-3-methylbenzimidazolium chloride derivative (**6a–d**, 0.5 mmol) was dissolved in 2,4-pentanedione (10 mL) and the solution was refluxed for 4 h in the presence of $ZnCl_2$ (10 mg). After the reaction, 2,4-pentanedione was removed by evaporation and the residues were subjected to PLC (silica gel, CHCl₃ then CHCl₃:MeOH = 85:15).

2,4,5,7,8-Pentamethylpyridazino[**1,6**-*a*]benzimidazolium chloride (7a). ¹H NMR (Me₂SO-*d*₆) δ 2.51 (s, 3H, 8-CH₃), 2.53 (s, 3H, 7-CH₃), 2.71 (s, 3H, 2-CH₃), 2.95 (s, 3H, 4-CH₃), 4.38 (s, 3H, 5-CH₃), 7.90 (s, 1H, 3-H), 8.09 (s, 1H, 6-H), 8.19 (s, 1H, 9-H); ¹³C NMR (Me₂SO-*d*₆) δ 18.2 (q, 4-CH₃), 19.8 (q, 8-CH₃), 20.5 (q, 7-CH₃), 20.9 (q, 2-CH₃), 33.3 (q, N-CH₃), 112.6 (2d, 6- and 9-C), 125.6 (s, 9a-C), 130.2 (d, 3-C), 130.8 (s, 5a-C), 134.0 (s, 4-C), 136.4 (s, 8-C), 138.7 (s, 4a-C), 140.1 (s, 7-C), 155.5 (s, 2-C).

2,4,5-Trimethylpyridazino[1,6-*a*]benzimidazolium chloride (7c). ¹H NMR (Me₂SO-*d*₆) δ 2.73 (s, 3H, 2-CH₃), 2.97 (s, 3H, 4-CH₃), 4.43 (s, 3H, N-CH₃), 7.81 (t, 1H, *J*=7.9 Hz, 8-H), 7.95 (t, 1H, *J*=7.9 Hz, 7-H), 7.98 (s, 1H, 3-H), 8.30 (d, 1H, *J*=7.9 Hz, 9-H), 8.42 (d, 1H, *J*=7.9 Hz, 6-H); ¹³C NMR (Me₂SO-*d*₆) δ 18.2 (q, 4-CH₃), 20.8 (q, 2-CH₃), 33.3 (q, N-CH₃), 113.0 (d, 9-C), 113.2 (d, 6-C), 126.2 (d, 8-C), 127.1 (s, 9a-C), 129.7 (d,

7-C), 131.0 (d, 3-C), 132.1 (s, 5a-C), 134.0 (s, 4-C), 139.6 (s, 4a-C), 155.7 (s, 2-C). UV λ_{max} nm; (H₂O) 236, 309.

2-(4-Acetyl-3-methylpyrazol-1-yl)-*N*,**4**,**5**-trimethylaniline (**8a**). ¹H NMR (CDCl₃) δ 2.20 (s, 3H, 4-CH₃), 2.28 (s, 3H, 5-CH₃), 2.45 (s, 3H, COCH₃), 2.55 (s, 3H, 3'-CH₃), 2.84 (s, 3H, N-CH₃), 5.20 (br s, 1H, NH), 6.61 (s, 1H, 6-H), 6.93 (s, 1H, 3-H), 8.02 (s, 1H, 5'-H); ¹³C NMR (CDCl₃) δ 14.2 (q, 3'-CH₃), 18.5 (q, 4-CH₃), 20.0 (q, 5-CH₃), 28.7 (q, COCH₃), 30.4 (q, N-CH₃), 113.3 (d, 6-C), 121.3 (s, 4'-C), 123.2 (s, 2-C), 124.4 (s, 4-C), 125.2 (d, 3-C), 134.6 (d, 5'-C), 138.2 (s, 5-C), 141.4 (1-C), 151.7 (s, 3'-C), 192.4 (s, COCH₃); MS *m*/*z* 257 (M⁺), 242 (M⁺-CH₃), 214 (M⁺-COCH₃).

2-(4-Acetyl-3-methylpyrazol-1-yl)-*N*,**4-dimethylaniline (8b).** ¹H NMR (CDCl₃) δ 2.29 (s, 3H, 4-CH₃), 2.46 (s, 3H, COCH₃), 2.56 (s, 3H, 3'-CH₃), 2.83 (s, 3H, N-CH₃), 5.22 (br s, 1H, NH), 6.69 (d, 1H, *J*=8.3 Hz, 6-H), 6.97 (s, 1H, 3-H), 7.10 (d, 1H, *J*=8.3 Hz, 5-H), 8.04 (s, 1H, 5'-H); ¹³C NMR (CDCl₃) δ 14.2 (q, 3'-CH₃), 20.1 (q, 4-CH₃), 28.7 (q, COCH₃), 30.4 (q, N-CH₃), 111.9 (d, 6-C), 121.4 (s, 4'-C), 124.8 (d, 3-C), 125.3 and 125.9 (each s, 2-and 4-C), 130.3 (d, 5-C), 134.6 (d, 5'-C), 141.3 (1-C), 151.8 (s, 3'-C), 192.4 (s, COCH₃); MS *m*/*z* 243 (M⁺), 200 (M⁺-COCH₃).

2-(4-Acetyl-3-methylpyrazol-1-yl)-*N*-methylaniline (8c). Recrystallization from MeOH gave light brown needles. Mp 114–116 °C; ¹H NMR (CDCl₃) δ 2.46 (s, 3H, COCH₃), 2.57 (s, 3H, 3'-CH₃), 2.86 (s, 3H, N-CH₃), 5.44 (br s, 1H, NH), 6.73 (ddd, 1H, J=1.2, 7.3, 7.3 Hz, 4-H), 6.77 (dd, 1H, J=1.2, 7.3 Hz, 3-H), 7.14 (dd, 1H, J = 1.2, 7.3 Hz, 6-H), 7.30 (ddd, 1H, J = 1.2, 7.3, 7.3 Hz, 5-H), 8.05 (s, 1H, 5'-H); ¹³C NMR (CDCl₃) δ 14.2 (q, 3'-CH₃), 28.7 (q, COCH₃), 30.2 (q, N-CH₃), 111.8 (d, 3-C), 116.3 (s, 4-C), 121.5 (s, 4'-C), 124.2 (d, 6-C), 125.3 (s, 2-C), 129.8 (d, 5-C), 134.7 (d, 5'-C), 143.5 (s, 1-C), 151.9 (s, 3'-C), 192.4 (s, COCH₃); UV λ_{max} nm, (pH 1) 264, (H₂O and pH 12) 239, 300; MS m/z 229 (M⁺). HRMS m/z M⁺ calcd for C₁₃H₁₅N₃O: 229.1214; found: 229.1215. Anal. calcd for C₁₃H₁₅N₃O: C, 68.10; H, 6.59; N, 18.33. Found: C, 67.96; H, 6.48; N, 18.09.

2-(4-Acetyl-3-methylpyrazol-1-yl)-*N*-methyl-5-nitroaniline (8d). Recrystallization from CHCl₃-hexane gave orange plates. Mp 176–179 °C; ¹H NMR (CDCl₃) δ 2.49 (s, 3H,

COCH₃), 2.59 (s, 3H, 3'-CH₃), 2.97 (s, 3H, N-CH₃), 6.44 (br s, 1H, NH), 7.29 (d, 1H, J=8.5 Hz, 3-H), 7.57 (dd, 1H, J=2.4, 8.5 Hz, 4-H), 7.59 (d, 1H, J=2.4 Hz, 6-H), 8.15 (s, 1H, 5'-H); ¹³C NMR (CDCl₃) δ 14.3 (q, 3'-CH₃), 28.8 (q, COCH₃), 30.1 (q, N-CH₃), 106.4 (d, 6-C), 110.9 (d, 4-C), 122.2 (s, 4'-C), 123.3 (d, 3-C), 128.9 (s, 2-C), 134.3 (d, 5'-C), 143.9 (s, 1-C), 148.4 (s, 5-C), 152.5 (s, 3'-C), 192.1 (s, COCH₃); MS m/z 274 (M⁺), 259 (M⁺-CH₃). Anal. calcd for C₁₃H₁₄N₄O₃: C, 56.93; H, 5.14; N, 20.43. Found: C, 56.83; H, 5.25; N, 20.40.

Acknowledgement

We would like to thank Professor Emeritus Y. Kawazoe of Nagoya City University for his helpful advice and encouragement.

References and Notes

- 1. References cited in ref 14.
- 2. Huang, G.-F. (Kohda, K.); Maeda, M.; Okamoto, T.; Kawazoe, Y. *Tetrahedron* **1975**, *31*, 1363.
- 3. Kohda, K.; Baba, K.; Kawazoe, Y. Chem. Pharm. Bull. 1986, 34, 2298.
- 4. Kohda, K.; Yasuda, M.; Ukai, H.; Baba, K.; Yamagata, Y.; Kawazoe, Y. *Tetrahedron* **1989**, *45*, 6367.
- 5. Kohda, K.; Kobayashi, I.; Itano, K.; Asano, S.; Kawazoe, Y. *Tetrahedron* **1993**, *49*, 3947.
- 6. Saga, T.; Kaiya, T.; Kohda, K. Nucleosides Nucleotides **1996**, *15*, 219.
- 7. Kaiya, T.; Ohta, M.; Kohda, K. *Tetrahedron* **1993**, *49*, 8795. 8. Kaiya, T.; Saga, T.; Yamagata, Y.; Kohda, K. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 2197.
- 9. Kuz'umenko, V. V.; Komissarov, V. N.; Simonov, A. M. *Khim. Geterotsikl. Soedin.* **1983**, *386* [C. A. 99, 212479g (1983)].
- 10. Pastor, J.; Siro, J. G.; Garcia-Navio, J. L.; Vaquero, J. J.; Alvarez-Builla, J.; Gago, F.; de Pascual-Teresa, B.; Pastor, M.; Rodrigo, M. M. J. Org. Chem. **1997**, *62*, 5476.
- 11. Wang, M.; Hecht, S. S. Chem. Res. Toxicol. 1997, 10, 772.
- 12. Somei, M.; Matsubara, M.; Kanda, Y.; Natsume, M. Chem. Pharm. Bull. 1978, 26, 2522.
- 13. Kuz'umenko, V. V.; Komissarov, V. N.; Simonov, A. M. *Khim. Geterotsikl. Soedin.* **1981**, *1497* [C. A. 96, 85465k (1982)].
- 14. Kaiya, T.; Aoyama, S.; Kohda, K. Bioorg. Med. Chem. Lett. 1999, 9, 961.